RafeeTalukderMD

Oncology • Houston, TX

Genitourinary Oncology, Melanoma, Sarcoma

Physician

Join to view full profile

Dr. Talukder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Talukder's full profile

Already have an account?

Office
1919 Old Spanish Trail
Houston, TX 77030

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2020 - 2023
Baylor College of MedicineResidency, Internal Medicine, 2016 - 2019
The University of Texas Health Science Center at San AntonioClass of 2016

Certifications & Licensure

TX State Medical License 2018 - 2026
WA State Medical License 2022 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Tanya Jindal, Cindy Jiang, Omar Alhalabi, Amanda Nizam, Charles Nguyen
European Urology Oncology. 2025-04-01
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, Leonidas N Diamantopoulos, Thomas Enright
Clinical Genitourinary Cancer. 2025-02-01
1 citations
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint I...
Dimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, Leonidas Diamantopoulos, Thomas Enright
Clinical Genitourinary Cancer. 2024-12-01

Abstracts/Posters

Differential Induction Among Younger Patients Diagnosed with Secondary Acute Myelogenous Leukemia Is Feasible By Cytogenetic/Molecular Risk Stratification
Rafee Talukder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Predictive Factors for Complete Remission and Survival in AML Patients Failing to Achieve Adequate Bone Marrow Day 14 Blast Eradication
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018